

COMPLIMENTARY CE SYMPOSIUM

Optimizing Outcomes in Late-Onset Pompe Disease:

Integrating New Therapies, Whole-Person Markers for Disease Monitoring, and Shared Decision-making Into Practice

Tuesday, February 6, 2024 5:45 AM – 6:15 AM – Registration 6:15 AM – 7:15 AM – CE Symposium Grand Manchester Hyatt San Diego + Grand Hall AB - Lobby Level



Priya S. Kishnani, MD, MBBS Duke University Medical Center Durham, North Carolina

Professor Mark Roberts, BSc, MBChB, FRCP, MD Salford Royal NHS Foundation Trust Salford, United Kingdom



Professor Dr. med. Benedikt Schoser, FEAN Ludwig-Maximilians-University Munich Munich, Germany ACTIVITY OVERVIEW – With the approval of 2 new entities, recent advances in enzyme replacement therapy (ERT) have created a paradigm shift in which healthcare providers (HCPs) have gone from only being able to use a single agent to being able to choose a treatment from multiple available options. Furthermore, the increasing adoption of newborn screening is allowing for greater appreciation of the early manifestations of late-onset Pompe disease (LOPD) and the opportunity to intervene earlier in the disease course. This activity will explore the new understanding around LOPD symptom onset and the efficacy of next-generation treatments to modify disease progression. Case-based scenarios that explore treatment initiation, how to monitor disease progression with the emerging biomarkers and patient-reported outcomes, strategies for multidisciplinary care that include shared-decision making, and considerations around treatment switching will be discussed.

TARGET AUDIENCE – This activity is intended for neuromuscular specialists, neurologists, clinical geneticists, genetic counselors, inherited metabolic disease/lysosomal storage disorder specialists, as well as other HCPs involved in the diagnosis and management of LOPD.

AGENDA

- The Impact of Our Evolving Understanding of LOPD on Treatment Goals
- Evaluating the Utility of Next-generation LOPD-Modifying Therapy
- Delivering Comprehensive Care for LOPD in an Evolving Treatment Era
- Q&A and Closing Remarks



This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC.



This activity is supported by educational grant from Amicus Therapeutics, Inc.

"WORLDSymposium™ has reviewed and approved this Satellite Symposium as appropriate for presentation as an independent educational activity held in conjunction with WORLDSymposium 2024. This Satellite Symposium is not part of the official WORLDSymposium program, and WORLDSymposium does not approve or endorse any commercial products or services discussed during the Satellite Symposium or offered for sale by the corporate supporter of the Satellite Symposium. This Satellite Symposium is not approved for CE by WORLDSymposium. This Satellite Symposium is approved for CE by WORLDSymposium. This Satellite Symposium is approved for CE by WORLDSymposium. This Satellite Symposium is approved for CE by WORLDSymposium. This Satellite Symposium is approved for CE by WORLDSymposium. This Satellite Symposium is approved for CE by WORLDSymposium. This Satellite Symposium is approved for CE by WORLDSymposium. This Satellite Symposium is approved for CE by WORLDSymposium. This Satellite Symposium is approved for CE by WORLDSymposium. This Satellite Symposium is approved for CE by WORLDSymposium. This Satellite Symposium is approved for CE by WORLDSymposium. This Satellite Symposium is approved for CE by WORLDSymposium. This Satellite Symposium is approved for CE by WORLDSymposium.

Eligibility: Registration for WORLDSymposium 2024 and an official WORLDSymposium badge are required to attend this satellite symposium."